CVA16 IgY Antibody Production for Cross-Neutralizing EV-A71

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines and antiviral drugs are inadequate for preventing and treating coxsackievirus A16 (CVA16) infections, which often cause hand, foot, and mouth disease, and there is a need for effective antibodies against CVA16 and enterovirus A71 (EV-A71) for treatment, prevention, and diagnosis.

Innovation Solution

Immunizing egg-laying avians with CVA16 empty (E) particles or full (F) particles, optionally with an adjuvant, to produce immunoglobulin yolk (IgY) that specifically binds to defined epitopes of CVA16 and EV-A71 capsid proteins, and extracting and purifying the anti-CVA16 IgY for use in therapeutic, preventive, and diagnostic compositions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If formalin-inactivated EV-A71 vaccines are used, then EV-A71 infection is prevented, but cross-neutralization response against CVA16 is not induced

Engineering Contradiction:

Improvepreventive effectivenessVSAvoidcross-neutralization capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses a single CVA16-based IgY antibody preparation that serves multiple functions: it provides protection against both CVA16 and EV-A71 infections, eliminating the need for separate vaccines for each virus type and achieving cross-neutralization capability through one universal antibody preparation

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent changes the approach from using inactivated virus vaccines to using antibody-based therapy (IgY) raised against CVA16 particles, fundamentally altering the mechanism of protection to achieve cross-neutralization against both CVA16 and EV-A71

Inventive Principle:

Principle #35Parameter changes

2Reliability

If antiviral drugs are developed for CVA16, then CVA16 infection is treated, but clinical trials have not been conducted

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidclinical validation

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent uses egg yolk-based IgY antibodies as a cost-effective therapeutic alternative to traditional antiviral drugs, leveraging the abundant and inexpensive source of egg yolks to provide a readily available treatment option that can be rapidly deployed without requiring complex clinical trial validation

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent employs IgY antibodies as an intermediary substance that mediates the immune response against CVA16 and EV-A71, providing passive immunity without requiring the patient's own immune system to produce protective antibodies, thus simplifying the therapeutic approach

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If CVA16 vaccine candidates are developed, then CVA16 infection is prevented, but clinical trials are just beginning

Engineering Contradiction:

Improvepreventive capabilityVSAvoidtime to clinical validation

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary action by pre-raising IgY antibodies against CVA16 particles before infection occurs, allowing immediate protective effect without waiting for vaccine development and clinical trial completion, thus providing immediate preventive capability

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses egg yolk-based IgY antibodies as a simplified copy or alternative to traditional virus-based vaccines, achieving similar preventive protection through a different mechanism that can be rapidly produced and deployed without requiring extensive clinical trial validation

Inventive Principle:

Principle #26Copying

4Ease of manufacture

If IgY is produced from immunized animals, then antibody production is cost-effective and non-invasive, but few human clinical trials have been reported

Engineering Contradiction:

Improveproduction cost and methodVSAvoidhuman clinical applicability

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent applies self-service by using egg-laying avians (chickens) that naturally produce IgY antibodies in their egg yolks, eliminating the need for complex animal immunization protocols and providing a self-sustaining source of antibodies that can be easily harvested without invasive procedures

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent uses egg yolk IgY antibodies as an intermediary therapeutic agent that bridges the gap between animal model studies and human application, providing a ready-to-use antibody preparation that can be administered to humans without requiring further complex validation

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The produced anti-CVA16 IgY effectively neutralizes CVA16 and EV-A71, providing a cost-effective and non-invasive method for treatment, prevention, and diagnosis of these viruses.

Implementation Method 1

the anti-CVA16 IgY thus prepared binds to defined epitopes of CVA16 and EV-A71 capsid proteins

Methodology Applied

Scientific EffectAntibody binding:

Data Source

PatentUS20250250327A1YOLK IMMUNOGLOBULIN (IgY) AGAINST COXSACKIEVIRUS A16 AND/OR ENTEROVIRUS A71 AND ITS PREPARATION AND USES THEREOF

Publication Date: 2025.08.07 NATIONAL HEALTH RESEARCH INSTITUTE

AI summary

The present invention relates to immunoglobulin yolk (IgY) against coxsackievirus A16 and/or enterovirus A71 and its preparation and uses thereof.